Shares of Healthcare Triangle (HCTI) tumbled 10.1% to $0.65 in after-hours trading after Nasdaq issued a formal delisting determination on October 1, stripping the company of any standard grace period to fix its sub-$1 stock price. For a company that has already exhausted extraordinary measures to stay listed, the clock is now ticking toward potential expulsion from the exchange.
• Three Reverse Splits in Three Years, and Nasdaq Has Seen Enough. Nasdaq issued the determination after HCTI received notice on Oct. 1, 2026, for failing the $1 minimum bid price rule, citing the company's ineligibility for a cure period because of reverse splits totaling 1-for-14,940. That staggering ratio spans a 1-for-10 split in May 2023 , a 1-for-249 split in August 2025 , and a 1-for-60 split in February 2026 . Nasdaq rules bar companies from repeatedly using reverse splits to game the bid-price requirement — and HCTI has clearly hit that wall.
• The Appeal Buys Time, But Not Confidence. Without an appeal by Oct. 8, trading would be suspended at the open on Oct. 12, followed by a Form 25-NSE filing; a hearings panel review request would stay the suspension pending a decision. HCTI is expected to request a hearing, but history offers little reassurance: the company faced a separate delisting threat in 2024 over a failure to meet the $2.5 million stockholders' equity requirement , and its financial position remains dire. Healthcare Triangle is currently in a challenging financial position with negative revenue growth, persistent losses, and negative equity.
• Dilution Has Been Relentless. The February 2026 reverse split reduced outstanding shares from about 45.4 million to roughly 757,000 , yet the share count has since ballooned back. The company issued 12,546,540 shares on July 24, 2026 , and in June closed a $3.6 million convertible-note deal with notes convertible at 85% of market price . Every capital raise at a discount accelerates the downward spiral in share price.
• What Delisting Means for Shareholders. If HCTI loses its Nasdaq listing, the stock would likely migrate to the over-the-counter market, where trading is thinner, institutional investors are largely absent, and retail investors already hold 99.68% of shares . At a market capitalization hovering around $1–2 million, the company would become nearly uninvestable for any fund with size constraints. The pattern — reverse split, dilute, repeat — has destroyed virtually all shareholder value, and the Nasdaq's refusal to grant another compliance window signals the endgame may be here.